Castle Biosciences Inc. (CSTL), a molecular diagnostics company, is slated to report financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024.
The company offers tests for skin cancers, Barrett's esophagus, mental health conditions and uveal melanoma. DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher Barrett's Esophagus Assay and IDgenetix, a cheek swab test to guide medication management for patients' neuropsychiatric conditions, such as depression and anxiety, are the company's commercially available tests.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.